课题基金 / 基金详情

AI & Personalized Therapeutics

AI & Personalized Therapeutics
人工智能
批准号：
468682
负责人：
Tamblyn Robyn M
金额：
$66.32万
依托单位：
McGill University
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-09-01 至 2027-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=468682&lang=en
关键词：
Artificial Intelligence Big Data Machine Learning Patient-Reported Outcomes Personalized Medicine Pharmacare Pragmatic Trials Predictive Analytics Reinforcement Learning

项目摘要

项目成果

Tamblyn Robyn M的其他基金

相似基金

相关文献

中文摘要
翻译
处方药在预防和治疗慢性健康问题方面发挥着越来越重要的作用。然而，药物目前并不像它们可能的那样有益。这是由于AP后有关它们的安全性和有效性的信息很少。
英文摘要
Prescription drugs play an expanding and essential role in preventing and treating chronic health problems. However, medications are currently not as beneficial as they could be. This is due to little information on their safety and effectiveness after ap
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluating the Accuracy of New Methods of Pharmacosurveillance: Computerized Administrative Data and Electronic Prescribing and Drug Management Systems
Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge
A Novel Monitoring Intervention to Optimize Mobility for Older Wheelchair Users: the MOvIT project
A Novel Method for Pharmacosurveillance: Combining an Electronic Prescribing and Drug Management System and Administrative Database
  • 批准号：
    171474
  • 项目类别：
    Operating Grants
  • 资助金额：
    $23.11万
  • 财政年份：
    2008
  • 负责人：
    Tamblyn Robyn M
  • 依托单位：
    McGill University
国内基金
海外基金
Scalable Learning and Optimization: High-dimensional Models and Online Decision-Making Strategies for Big Data Analysis